vs

Side-by-side financial comparison of DATASEA INC. (DTSS) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $13.0M, roughly 1.5× DATASEA INC.). DATASEA INC. runs the higher net margin — -4.1% vs -177.4%, a 173.3% gap on every dollar of revenue. On growth, STANDARD BIOTOOLS INC. posted the faster year-over-year revenue change (-11.5% vs -36.5%). Over the past eight quarters, DATASEA INC.'s revenue compounded faster (206.5% CAGR vs -12.2%).

Datasea Inc. develops intelligent smart city solutions including AI-powered public security systems, IoT-enabled surveillance devices and big data analytics services. It mainly serves public security, education and commercial real estate sectors, with core operations in China and ongoing expansion into Southeast Asia.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

DTSS vs LAB — Head-to-Head

Bigger by revenue
LAB
LAB
1.5× larger
LAB
$19.6M
$13.0M
DTSS
Growing faster (revenue YoY)
LAB
LAB
+25.0% gap
LAB
-11.5%
-36.5%
DTSS
Higher net margin
DTSS
DTSS
173.3% more per $
DTSS
-4.1%
-177.4%
LAB
Faster 2-yr revenue CAGR
DTSS
DTSS
Annualised
DTSS
206.5%
-12.2%
LAB

Income Statement — Q2 FY2026 vs Q3 FY2025

Metric
DTSS
DTSS
LAB
LAB
Revenue
$13.0M
$19.6M
Net Profit
$-538.8K
$-34.7M
Gross Margin
9.2%
48.5%
Operating Margin
-4.0%
-168.5%
Net Margin
-4.1%
-177.4%
Revenue YoY
-36.5%
-11.5%
Net Profit YoY
52.6%
-28.8%
EPS (diluted)
$-0.06
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DTSS
DTSS
LAB
LAB
Q4 25
$13.0M
Q3 25
$13.8M
$19.6M
Q2 25
$19.7M
$21.8M
Q1 25
$10.4M
$40.8M
Q4 24
$20.5M
Q3 24
$21.1M
$22.1M
Q2 24
$4.4M
$22.5M
Q1 24
$1.4M
$45.5M
Net Profit
DTSS
DTSS
LAB
LAB
Q4 25
$-538.8K
Q3 25
$-201.0K
$-34.7M
Q2 25
$-204.4K
$-33.5M
Q1 25
$-1.8M
$-26.0M
Q4 24
$-1.1M
Q3 24
$-2.0M
$-26.9M
Q2 24
$-5.4M
$-45.7M
Q1 24
$-4.1M
$-32.2M
Gross Margin
DTSS
DTSS
LAB
LAB
Q4 25
9.2%
Q3 25
8.5%
48.5%
Q2 25
7.8%
48.8%
Q1 25
2.9%
48.4%
Q4 24
2.0%
Q3 24
0.9%
54.9%
Q2 24
6.6%
46.1%
Q1 24
0.7%
53.1%
Operating Margin
DTSS
DTSS
LAB
LAB
Q4 25
-4.0%
Q3 25
-2.1%
-168.5%
Q2 25
-0.6%
-118.1%
Q1 25
-17.1%
-80.8%
Q4 24
-6.1%
Q3 24
-9.6%
-120.9%
Q2 24
-123.1%
-134.5%
Q1 24
-297.0%
-132.2%
Net Margin
DTSS
DTSS
LAB
LAB
Q4 25
-4.1%
Q3 25
-1.5%
-177.4%
Q2 25
-1.0%
-153.7%
Q1 25
-17.2%
-63.8%
Q4 24
-5.6%
Q3 24
-9.3%
-122.0%
Q2 24
-123.3%
-203.3%
Q1 24
-299.5%
-70.6%
EPS (diluted)
DTSS
DTSS
LAB
LAB
Q4 25
$-0.06
Q3 25
$-0.02
$-0.09
Q2 25
$0.12
$-0.09
Q1 25
$-0.24
$-0.07
Q4 24
$-0.16
Q3 24
$-0.49
$-0.07
Q2 24
$-2.10
$-0.12
Q1 24
$-1.55
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DTSS
DTSS
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$3.5M
$399.7M
Total Assets
$8.6M
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DTSS
DTSS
LAB
LAB
Q4 25
Q3 25
$129.4M
Q2 25
$158.6M
Q1 25
$150.9M
Q4 24
Q3 24
$210.6M
Q2 24
$269.8M
Q1 24
$287.1M
Total Debt
DTSS
DTSS
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
DTSS
DTSS
LAB
LAB
Q4 25
$3.5M
Q3 25
$3.0M
$399.7M
Q2 25
$3.0M
$424.5M
Q1 25
$2.8M
$454.6M
Q4 24
$3.2M
Q3 24
$4.1M
$489.3M
Q2 24
$-236.7K
$510.3M
Q1 24
$1.3M
$577.3M
Total Assets
DTSS
DTSS
LAB
LAB
Q4 25
$8.6M
Q3 25
$7.7M
$539.6M
Q2 25
$6.7M
$557.0M
Q1 25
$6.2M
$579.6M
Q4 24
$5.9M
Q3 24
$8.0M
$681.5M
Q2 24
$3.3M
$708.7M
Q1 24
$3.4M
$777.7M
Debt / Equity
DTSS
DTSS
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DTSS
DTSS
LAB
LAB
Operating Cash FlowLast quarter
$661.7K
$-22.2M
Free Cash FlowOCF − Capex
$-23.1M
FCF MarginFCF / Revenue
-118.1%
Capex IntensityCapex / Revenue
4.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DTSS
DTSS
LAB
LAB
Q4 25
$661.7K
Q3 25
$879.3K
$-22.2M
Q2 25
$-589.2K
$-20.7M
Q1 25
$-197.9K
$-30.3M
Q4 24
$-854.9K
Q3 24
$-732.7K
$-27.9M
Q2 24
$-444.5K
$-39.0M
Q1 24
$-321.1K
$-62.5M
Free Cash Flow
DTSS
DTSS
LAB
LAB
Q4 25
Q3 25
$-23.1M
Q2 25
$-590.1K
$-22.6M
Q1 25
$-197.9K
$-35.3M
Q4 24
$-859.4K
Q3 24
$-735.4K
$-30.1M
Q2 24
$-447.7K
$-41.0M
Q1 24
$-321.1K
$-63.3M
FCF Margin
DTSS
DTSS
LAB
LAB
Q4 25
Q3 25
-118.1%
Q2 25
-3.0%
-103.6%
Q1 25
-1.9%
-86.6%
Q4 24
-4.2%
Q3 24
-3.5%
-136.4%
Q2 24
-10.3%
-182.2%
Q1 24
-23.2%
-138.9%
Capex Intensity
DTSS
DTSS
LAB
LAB
Q4 25
Q3 25
4.5%
Q2 25
0.0%
8.7%
Q1 25
0.0%
12.4%
Q4 24
0.0%
Q3 24
0.0%
10.2%
Q2 24
0.1%
8.6%
Q1 24
0.0%
1.7%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DTSS
DTSS

Segment breakdown not available.

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons